CompletedNot Applicable

Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa

Burkina Faso, Côte d’Ivoire, Mali885 participantsStarted 2015-06

Plain-language summary

The objective of the study is to evaluate the feasibility and interest of a HIV quarterly preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help reducing HIV incidence in this key population, their female partners, and the general population. This interventional, open label, multicenter, multidisciplinary cohort study will be conducted in Burkina Faso, Ivory Coast, Mali and Togo. All participants will receive a HIV quarterly preventive global care including: i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) counselling adapted for MSM, and v) the provision of condoms and lubricants.

Who can participate

Age range

18 Years

Sex

MALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Man over 18 years * Reporting at least one anal sex (passive or active) with another man within the last three months * Able to reach the local site of the study * Agreeing to participate in the study and signing the informed consent form Exclusion Criteria: * History of antiretroviral therapy (except for pre- or post-exposure prophylaxis) * Participation in another biomedical or behavioral research on HIV or sexually transmitted infections * Impairment of the person making his participation in the study, or information understanding, difficult or impossible * Predictable protocol violation (geographical distance or other reasons)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of people followed after 3 years compared to the number of persons included (retention in the program)

Timeframe: 3 years

Percentage of performed visits/scheduled visits

Timeframe: 3 years

Percentage of performed tests/scheduled tests

Timeframe: 3 years

Incidence of sexually transmitted infections

Timeframe: 3 years

Number of unprotected anal sex

Timeframe: 3 years

Antiretroviral therapy initiation probability in HIV-positive MSM

Timeframe: 3 years

Antiretroviral therapy maintenance probability in HIV-positive MSM

Timeframe: 3 years

Trial details

NCT IDNCT02626286

SponsorANRS, Emerging Infectious Diseases

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2021-01-05

View on ClinicalTrials.gov More HIV Infection trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

MALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of people followed after 3 years compared to the number of persons included (retention in the program)

Timeframe: 3 years

Percentage of performed visits/scheduled visits

Timeframe: 3 years

Percentage of performed tests/scheduled tests

Timeframe: 3 years

Incidence of sexually transmitted infections

Timeframe: 3 years

Number of unprotected anal sex

Timeframe: 3 years

Antiretroviral therapy initiation probability in HIV-positive MSM

Timeframe: 3 years

Antiretroviral therapy maintenance probability in HIV-positive MSM

Timeframe: 3 years